{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:57:30Z","timestamp":1778860650688,"version":"3.51.4"},"reference-count":31,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2018,10,17]],"date-time":"2018-10-17T00:00:00Z","timestamp":1539734400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate the efficacy and safety of lesinurad for the treatment of hyperuricemia in patients with gout.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Systematic review and meta\u2010analysis of randomized controlled trials (<jats:styled-content style=\"fixed-case\">RCTs<\/jats:styled-content>).<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients or Participants<\/jats:title><jats:p>Five <jats:styled-content style=\"fixed-case\">RCT<\/jats:styled-content>s, which included 1959 patients, compared the efficacy and safety of lesinurad in patients with hyperuricemia associated with gout.<\/jats:p><\/jats:sec><jats:sec><jats:title>Measurements and Results<\/jats:title><jats:p>Relevant studies were identified from PubMed, <jats:styled-content style=\"fixed-case\">EMBASE<\/jats:styled-content>, Cochrane Library databases, and the ClinicalTrials.gov registry. Two reviewers independently assessed the studies. Individual effect sizes were standardized, and a meta\u2010analysis was conducted to calculate the pooled effect size by using a random\u2010effect model. The primary outcomes were the proportion of patients achieving target serum uric acid (<jats:styled-content style=\"fixed-case\">sUA<\/jats:styled-content>) levels by month 6 and the mean <jats:styled-content style=\"fixed-case\">sUA<\/jats:styled-content> levels at month 6 and month 12. Gout\u2010related outcomes were also assessed. The secondary outcome was the number of treatment\u2010emergent adverse events (<jats:styled-content style=\"fixed-case\">TEAE<\/jats:styled-content>s). Compared with xanthine oxidase inhibitor (<jats:styled-content style=\"fixed-case\">XOI<\/jats:styled-content>) monotherapy, lesinurad 200\u00a0mg or 400\u00a0mg in combination with allopurinol or febuxostat exhibited a higher proportion of patients achieving target <jats:styled-content style=\"fixed-case\">sUA<\/jats:styled-content> levels of &lt; 6.0\u00a0mg\/dl or &lt; 5.0\u00a0mg\/dl, respectively, by month 6. Lesinurad\u2010plus\u2010<jats:styled-content style=\"fixed-case\">XOI<\/jats:styled-content> groups also significantly sustained lower mean <jats:styled-content style=\"fixed-case\">sUA<\/jats:styled-content> levels at month 6 and month 12 compared to <jats:styled-content style=\"fixed-case\">XOI<\/jats:styled-content> alone group. In gout\u2010related outcomes, no significant treatment group differences favored lesinurad. The number of <jats:styled-content style=\"fixed-case\">TEAE<\/jats:styled-content>s was comparable between the lesinurad 200\u00a0mg\u2010plus\u2010<jats:styled-content style=\"fixed-case\">XOI<\/jats:styled-content> group and the <jats:styled-content style=\"fixed-case\">XOI<\/jats:styled-content>\u2010monotherapy group. Although lesinurad 400\u00a0mg monotherapy demonstrated superior efficacy compared with placebo, significantly more <jats:styled-content style=\"fixed-case\">TEAE<\/jats:styled-content>s occurred.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Although the combination of lesinurad 200\u00a0mg and <jats:styled-content style=\"fixed-case\">XOI<\/jats:styled-content> is effective and well tolerated for treating patients with gout who have not achieved an adequate response to <jats:styled-content style=\"fixed-case\">XOI<\/jats:styled-content> monotherapy, clinical gout\u2010related outcomes were not improved. Therefore, additional studies investigating the long\u2010term clinical implication of lesinurad are warranted.<\/jats:p><\/jats:sec>","DOI":"10.1002\/phar.2183","type":"journal-article","created":{"date-parts":[[2018,9,24]],"date-time":"2018-09-24T02:28:28Z","timestamp":1537756108000},"page":"1106-1119","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy and Safety of Lesinurad in Patients with Hyperuricemia Associated with Gout: A Systematic Review and Meta\u2010Analysis of Randomized Controlled Trials"],"prefix":"10.1002","volume":"38","author":[{"given":"Jie\u2010Ying","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Family Medicine Taipei Medical University\u2010Shuang Ho Hospital New Taipei City Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya\u2010Ting","family":"Chang","sequence":"additional","affiliation":[{"name":"School of Medicine College of Medicine Taipei Medical University Taipei Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying\u2010Chin","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Family Medicine Taipei Medical University\u2010Shuang Ho Hospital New Taipei City Taiwan"},{"name":"Department of Family Medicine School of Medicine College of Medicine Taipei Medical University Taipei Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia\u2010Hwa","family":"Lee","sequence":"additional","affiliation":[{"name":"School of Medical Laboratory Science and Biotechnology College of Medical Science and Technology Taipei Medical University Taipei Taiwan"},{"name":"Comprehensive Cancer Center of Taipei Medical University Taipei Taiwan"},{"name":"Department of Laboratory Medicine Taipei Medical University\u2010Shuang Ho Hospital New Taipei City Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"El\u2010Wui","family":"Loh","sequence":"additional","affiliation":[{"name":"Center for Evidence\u2010Based Health Care Department of Medical Research Taipei Medical University\u2010Shuang Ho Hospital New Taipei City Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei\u2010Yi","family":"Wu","sequence":"additional","affiliation":[{"name":"Center for Evidence\u2010Based Health Care Department of Medical Research Taipei Medical University\u2010Shuang Ho Hospital New Taipei City Taiwan"},{"name":"Division of Nephrology Department of Internal Medicine Taipei Medical University\u2010Shuang Ho Hospital New Taipei City Taiwan"},{"name":"Department of Internal Medicine School of Medicine College of Medicine Taipei Medical University Taipei Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu\u2010Sheng","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine School of Medicine College of Medicine Taipei Medical University Taipei Taiwan"},{"name":"Division of Allergy, Immunology, and Rheumatology Department of Internal Medicine Taipei Medical University\u2010Shuang Ho Hospital New Taipei City Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1994-834X","authenticated-orcid":false,"given":"Ka\u2010Wai","family":"Tam","sequence":"additional","affiliation":[{"name":"Center for Evidence\u2010Based Health Care Department of Medical Research Taipei Medical University\u2010Shuang Ho Hospital New Taipei City Taiwan"},{"name":"Division of General Surgery Department of Surgery Taipei Medical University\u2010Shuang Ho Hospital New Taipei City Taiwan"},{"name":"Department of Surgery School of Medicine College of Medicine Taipei Medical University Taipei Taiwan"},{"name":"Cochrane Taiwan Taipei Medical University Taipei Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,10,17]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21772"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex156"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar3199"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60883-7"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2015.91"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209707"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203325"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-013-0084-0"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2013.05.004"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep33082"},{"key":"e_1_2_7_12_1","first-page":"651","article-title":"Benzbromarone withdrawn from the European market: another case of \u201cabsence of evidence is evidence of absence\u201d?","volume":"22","author":"Jansen TL","year":"2004","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200831080-00002"},{"key":"e_1_2_7_14_1","first-page":"897190017734427","article-title":"Lesinurad, a selective URAT\u20101 inhibitor with a novel mechanism in combination with a xanthine oxidase inhibitor, for hyperuricemia associated with gout","volume":"1","author":"Huneycutt E","year":"2017","journal-title":"J Pharm Pract"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-016-1107-x"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0550-y"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-017-0461-y"},{"key":"e_1_2_7_18_1","volume-title":"Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011)","author":"Deeks JJ","year":"2011"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2009.06.006"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90046-2"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209213"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40159"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207919"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39840"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex350"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.7326\/M16-0570"},{"key":"e_1_2_7_27_1","unstructured":"AstraZenecaAB.ZURAMPIC (lesinurad) tablets for oral use: US prescribing information.2015. Available fromhttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/207988lbl.pdf. Accessed December 31 2017."},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000035"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13427"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20221"},{"key":"e_1_2_7_31_1","unstructured":"U.S. Food and Drug Administration.FDA Drug Safety Communication: FDA to evaluate increased risk of heart\u2010related death and death from all causes with the gout medicine febuxostat (Uloric) [Online].2017. Available from:https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm584702.htm. Accessed December 10 2017."},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h4848"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.2183","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2183","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:30:33Z","timestamp":1761049833000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.2183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,17]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["10.1002\/phar.2183"],"URL":"https:\/\/doi.org\/10.1002\/phar.2183","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,17]]},"assertion":[{"value":"2018-10-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}